Editas Medicine Inc (EDIT) concluded trading on Wednesday at a closing price of $2.05, with 9.1 million shares of worth about $18.65 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -45.19% during that period and on March 05, 2025 the price saw a gain of about 16.48%. Currently the company’s common shares owned by public are about 82.54M shares, out of which, 81.78M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of 11.41% in past 5 days and over the past one month there was a price change of 61.42%. Year-to-date (YTD), EDIT shares are showing a performance of 61.42% which decreased to -80.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.12 but also hit the highest price of $9.95 during that period. The average intraday trading volume for Editas Medicine Inc shares is 4.16 million. The stock is currently trading 20.38% above its 20-day simple moving average (SMA20), while that difference is up 40.53% for SMA50 and it goes to -38.32% lower than SMA200.
Editas Medicine Inc (NASDAQ: EDIT) currently have 82.54M outstanding shares and institutions hold larger chunk of about 62.84% of that.
The stock has a current market capitalization of $169.22M and its 3Y-monthly beta is at 2.04. It has posted earnings per share of -$2.56 in the same period. It has Quick Ratio of 3.75 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 16.95% while standing at 17.98% over the month.
Stock’s fiscal year EPS is expected to rise by 51.59% while it is estimated to increase by 11.73% in next year. EPS is likely to grow at an annualized rate of 22.01% for next 5-years, compared to annual growth of 2.88% made by the stock over the past 5-years.
Stock get an Equal weight rating from Wells Fargo on December 11, 2024.
